Advisory Boards

The Clinical Advisory Board (CAB) will organise a consensus meeting with WP2, WP3, WP5, and patient organisations to define inclusion and exclusion criteria for the new patient cohort (Major Depressive Disorder, MDD). Furthermore, it will review the Schizophrenia (SZ) and Alzheimer Disease (AD) inclusion and exclusion criteria from PRISM 1 in light of the newly added digital technologies, provide support to PRISM 2 members concerning the “PRISM 2 – VALIDATE” study, and review and assess the results of the interim evaluation.

Prof. Dr. Martien Kas

Professor of Behavioural Neuroscience

Phone: +31 (0)50 363 238 1

Send E-Mail
Prof. Dr. Brenda Penninx

Professor of Psychiatric Epidemiology

Phone: +31 (0)20 788 567 4

Send E-Mail
Prof. Dr. Nic van der Wee

Psychiatrist


Send E-Mail
Prof. Dr. Yolande Pijnenburg

Professor of Neurology


Send E-Mail
Dr. Hugh Marston, F.R.S.B.

Senior Vice President & Head of Global CNS Disease Research


Send E-Mail
Dr Gerard Dawson

CEO P1vital Ltd


Send E-Mail
Dr Amy Bilderbeck

Director of Scientific Research


Send E-Mail
Dr. Celso Arango

Consultant Psychiatrist & Head of Division


Send E-Mail
Dr. Stephanie Bauduin

Psychologist


Send E-Mail
Dr. José Luis Ayuso Mateos

Chief of Psychiatry


Send E-Mail
Dr. Javier-David Lopez-Morinigo

Consultant Psychiatrist


Send E-Mail
Dr. Alba Vieira Campos

Neurologist


Send E-Mail
Dr. Vikas Sharma

Global Head Medicine CNS


Send E-Mail
Dr. Thomas Tzschentke

Senior Translational Medicine & Clinical Biomarker Lead – CNS Diseases


Send E-Mail
Dr. Joachim Scholpp

Global Head Translational Medicine CNS


Send E-Mail
Ailidh Finlayson

Scientific Support


Send E-Mail
Ana Ortiz-Tallo

Psychologist


Send E-Mail
Oliver Schofield

Clinical Project Manager


Send E-Mail

The Scientific and Ethical Advisory Board (SEAB) is a consultative body which is formed to ensure the highest possible scientific performance, adherence to ethics requirements, and the overall quality of PRISM 2 results. The following renowned experts from relevant scientific fields have agreed to be part of the PRISM 2 SEAB.

Prof. Dr. Deanna Barch

Departments of Psychology, Psychiatry, and Radiology
Washington University, WA, USA


Send E-Mail
Prof. Dr. Marcella Rietschel

Central Institute for Mental Health
Mannheim, Germany


Send E-Mail
Prof. Dr. Will Carpenter

Department of Psychiatry
University of Maryland, MD, USA


Send E-Mail

The Impact and Innovation Board (IIB) together with ECNP will be responsible for designing a structured plan for dissemination and communication and overseeing the exploitation of programme results by monitoring the steps being taken. Together with the COOR-team it will oversee the comprehensive internal and external dissemination of project results and knowledge. Importantly, prior to every general assembly (GA) meeting, every site principal investigator (PI) of PRISM 2 will be interviewed about their plans for dissemination in the coming year, and whether any new intellectual property (IP) emerged that may need protection.

Prof. Dr. Martien Kas

Professor of Behavioural Neuroscience

Phone: +31 (0)50 363 238 1

Send E-Mail
Dr. Hugh Marston, F.R.S.B.

Senior Vice President & Head of Global CNS Disease Research


Send E-Mail
Dr. Alba Vieira Campos

Neurologist


Send E-Mail
Dr. Lee Lancashire

Chief Information Officer


Send E-Mail
Dr. Stephanie Bauduin

Psychologist


Send E-Mail
Dr. Maarten Mennes

Head of MR Analysis & Quality Manager


Send E-Mail
Juliane Dittrich

Project Manager

Phone: +49 (0)8141 625 285 76

Send E-Mail
Ligia Bohn

Communications Manager

Phone: +31 (0)85 782 667 0

Send E-Mail
Follow us on social media:
Facebook Twitter